Why the study?
Anthracycline-associated cardiotoxicity in childhood cancer survivors may relate to global or segmental left ventricular abnormalities from thromboembolic events and myocardial microinfarcts.
Does prior anthracycline chemotherapy cause subclinical global or segmental left ventricular dysfunction in asymptomatic childhood cancer survivors?
Population
41 childhood cancer survivors with normal LV fractional shortening >1 year after anthracycline chemotherapy and cancer-free controls
Comparison
Anthracycline-treated childhood cancer survivors vs cancer-free control children
Design
Case-control study
Follow-up
Median 4.73 years
Key result
In 2017, an estimated 1,688,780 new cancer cases and 600,920 cancer deaths are expected to occur in the United States, with overall cancer death rates having declined by 25% from 1991 to 2014.
Authors
Loading...
Subclinical LV strain reduction occurs in anthracycline-treated survivors despite normal FS; leaves open whether routine speckle-tracking screening improves outcomes.
Does prior anthracycline chemotherapy cause subclinical global or segmental left ventricular dysfunction in asymptomatic childhood cancer survivors?
Speckle-tracking echocardiography reveals subclinical global left ventricular dysfunction in asymptomatic childhood cancer survivors treated with anthracyclines, even when conventional fractional shortening is normal.
Akam‐Venkata et al. (2019) conducted a review in Cancer (n=1,688,780). In 2017, an estimated 1,688,780 new cancer cases and 600,920 cancer deaths are expected to occur in the United States, with overall cancer death rates having declined by 25% from 1991 to 2014.